These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11424009)

  • 1. Protection from secondary human immunodeficiency virus type 1 infection in chimpanzees suggests the importance of antigenic boosting and a possible role for cytotoxic T cells.
    Balla-Jhagjhoorsingh SS; Mooij P; ten Haaft PJ; Bogers WM; Teeuwsen VJ; Koopman G; Heeney JL
    J Infect Dis; 2001 Jul; 184(2):136-43. PubMed ID: 11424009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of beta-chemokines in contrast to infected humans.
    Ondoa P; Vereecken C; Fransen K; Colebunders R; van der Groen G; Heeney JL; Kestens L
    J Med Virol; 2003 Mar; 69(3):297-305. PubMed ID: 12526038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
    Masopust D
    J Intern Med; 2009 Jan; 265(1):125-37. PubMed ID: 19093965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rectal transmission of human immunodeficiency virus type 1 to chimpanzees.
    Fultz PN; Wei Q; Yue L
    J Infect Dis; 1999 May; 179 Suppl 3():S418-21. PubMed ID: 10099110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.
    Ahlers JD; Belyakov IM
    Trends Immunol; 2010 Mar; 31(3):120-30. PubMed ID: 20089450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles.
    Vajdy M; Gardner J; Neidleman J; Cuadra L; Greer C; Perri S; O'Hagan D; Polo JM
    J Infect Dis; 2001 Dec; 184(12):1613-6. PubMed ID: 11740739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
    Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
    J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA; Oka S; Takiguchi M
    Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting.
    Paris R; Bejrachandra S; Karnasuta C; Chandanayingyong D; Kunachiwa W; Leetrakool N; Prakalapakorn S; Thongcharoen P; Nittayaphan S; Pitisuttithum P; Suriyanon V; Gurunathan S; McNeil JG; Brown AE; Birx DL; de Souza M
    Tissue Antigens; 2004 Sep; 64(3):251-6. PubMed ID: 15304005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
    Matano T; Kano M; Nakamura H; Takeda A; Nagai Y
    J Virol; 2001 Dec; 75(23):11891-6. PubMed ID: 11689672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes.
    Koopman G; Haaksma AG; ten Velden J; Hack CE; Heeney JL
    AIDS Res Hum Retroviruses; 1999 Mar; 15(4):365-73. PubMed ID: 10082120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active and passive immunization against HIV type 1 infection in chimpanzees.
    Murthy KK; Cobb EK; Rouse SR; McClure HM; Payne JS; Salas MT; Michalek GR
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S271-6. PubMed ID: 9814955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.